The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment ...

The FDA has expanded the approval of Valtoco (diazepam nasal spray) to include treatment of seizure clusters in patients aged 2 to 5 years.

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD ... and says the drug would need to be between 25% and 52% cheaper to meet its value threshold.

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of seizure clusters (also known as "acute repetitive ...